Parkinson’s Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Parkinson’s Disease Overview

Parkinson’s disease (PD) is a neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.

“Parkinson’s Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson’s Disease Market.

The Parkinson’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Parkinson’s Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Parkinson’s Disease treatment therapies with a considerable amount of success over the years. Parkinson’s Disease Key players such as – Cantabio Pharmaceuticals, Treefrog Therapeutics, Nobilis Therapeutics, AstraZeneca, Lundbeck A/S, Kissei Pharmaceutical, Roche, Pharma Two B, Abbvie, Cerevel Therapeutics, and others, are developing therapies for the Parkinson’s Disease treatment 
• Parkinson’s Disease Emerging therapies such as – CB101, Neural microtissues, NBTX 001, MEDI1341, Lu AF28996, KDT 3594, Prasinezumab, P2B001, ABBV-951, Tavapadon, and others are expected to have a significant impact on the Parkinson’s Disease market in the coming years.   

Route of Administration

Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Parkinson’s Disease Pipeline Therapeutics Assessment

• Parkinson’s Disease Assessment by Product Type
• Parkinson’s Disease By Stage and Product Type
• Parkinson’s Disease Assessment by Route of Administration
• Parkinson’s Disease By Stage and Route of Administration
• Parkinson’s Disease Assessment by Molecule Type
• Parkinson’s Disease by Stage and Molecule Type

DelveInsight’s Parkinson’s Disease Report covers around 150+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Parkinson’s Disease Therapeutics Market include:

Key companies developing therapies for Parkinson’s Disease treatment are – Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences,  Orpheris, Inc., Alkahest, Inc., and others.

Emerging Parkinson’s Disease Drugs Under Different Phases of Clinical Development Include:

• CB101: Cantabio Pharmaceuticals
• Neural microtissues: Treefrog Therapeutics
• NBTX 001: Nobilis Therapeutics
• MEDI1341: AstraZeneca
• Lu AF28996: Lundbeck A/S
• KDT 3594: Kissei Pharmaceutical
• Prasinezumab: Roche
• P2B001: Pharma Two B
• ABBV-951: Abbvie
• Tavapadon: Cerevel Therapeutics

Get a Free Sample PDF Report to know more about Parkinson’s Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights

Parkinson’s Disease Pipeline Analysis:

The Parkinson’s Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson’s Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.
• Parkinson’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Parkinson’s Disease product details are provided in the report. Download the Parkinson’s Disease pipeline report to learn more about the emerging Parkinson’s Disease therapies

Parkinson’s Disease Pipeline Market Drivers

• Increasing prevalence of Acute Myeloid Leukemia patients
• Robust clinical-stage pipeline

Parkinson’s Disease Pipeline Market Barriers

• Lack of awareness and delayed diagnosis
• Unavailability of disease modifying treatments for Parkinson disease

Scope of Parkinson’s Disease Pipeline Drug Insight    

• Coverage: Global
• Key Parkinson’s Disease Companies: Cantabio Pharmaceuticals, Treefrog Therapeutics, Nobilis Therapeutics, AstraZeneca, Lundbeck A/S, Kissei Pharmaceutical, Roche, Pharma Two B, Abbvie, Cerevel Therapeutics, and others
• Key Parkinson’s Disease Therapies: CB101, Neural microtissues, NBTX 001, MEDI1341, Lu AF28996, KDT 3594, Prasinezumab, P2B001, ABBV-951, Tavapadon, and others
• Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies
• Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers 

Request for Sample PDF Report for Parkinson’s Disease Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Parkinson’s Disease drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting